



The future of bioanalysis for biologics development

What analytical platforms were most utilized for...


Pharmacokinetics?




Pharmacodynamics?



Oligonucleotide quantitation?



Antibody biologic quantitation?



Types of biologic therapies studied included:



Monoclonal antibodies 58%



Bispecific antibodies 39%



Antibody-drug conjugates 35%



Gene therapies 40%




Vaccines 28%



RNA-based drugs (ASO, siRNA, miRNA, aptamers etc.) 27%



Fusion proteins 23%




Prodrugs 23%




Blood or blood products 21%


The proportion of biologics studies outsourced:




How much of a biologics workflow was automated?




Will there be an increase in automation in data processing workflows for biologics bioanalysis?




Automated platforms currently utilized included:



The main outsourcing challenges for biologics bioanalysis were:



The greatest benefits for pharma companies in outsourcing bioanalysis for biologics were:



This infographic has been created as part of a Bioanalysis Zone feature in association with Altasciences.